MARKET

CLRB

CLRB

Cellectar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.600
0.000
0.00%
Closed 16:00 10/14 EDT
OPEN
1.630
PREV CLOSE
1.600
HIGH
1.700
LOW
1.560
VOLUME
84.81K
TURNOVER
--
52 WEEK HIGH
3.750
52 WEEK LOW
1.220
MARKET CAP
15.03M
P/E (TTM)
-0.4447
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLRB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLRB News

  • Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
  • GlobeNewswire.6d ago
  • Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
  • GlobeNewswire.09/30 13:30
  • 23 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.09/25 12:17
  • OSTK, NBEV among premarket gainers
  • Seeking Alpha - Article.09/24 13:17

More

Industry

Pharmaceuticals
-0.01%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About CLRB

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.
More

Webull offers Cellectar Biosciences Inc (CLRB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.